Unknown

Dataset Information

0

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.


ABSTRACT: The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF). The HGF/c-MET axis is often dysregulated in tumors. c-MET activation can be caused by MET gene amplification, activating mutations, and auto- or paracrine mechanisms. Thus, c-MET inhibitors are under development as anticancer drugs. Tivantinib (ARQ 197) was reported as a small-molecule c-MET inhibitor and early clinical studies suggest antitumor activity. To assess whether the antitumor activity of tivantinib was due to inhibition of c-MET, we compared the activity of tivantinib with other c-MET inhibitors in both c-MET-addicted and nonaddicted cancer cells. As expected, other c-MET inhibitors, crizotinib and PHA-665752, suppressed the growth of c-MET-addicted cancers, but not the growth of cancers that are not addicted to c-MET. In contrast, tivantinib inhibited cell viability with similar potency in both c-MET-addicted and nonaddicted cells. These results suggest that tivantinib exhibits its antitumor activity in a manner independent of c-MET status. Tivantinib treatment induced a G(2)-M cell-cycle arrest in EBC1 cells similarly to vincristine treatment, whereas PHA-665752 or crizotinib treatment markedly induced G(0)-G(1) cell-cycle arrest. To identify the additional molecular target of tivantinib, we conducted COMPARE analysis, an in silico screening of a database of drug sensitivities across 39 cancer cell lines (JFCR39), and identified microtubule as a target of tivantinib. Tivantinib-treated cells showed typical microtubule disruption similar to vincristine and inhibited microtubule assembly in vitro. These results suggest that tivantinib inhibits microtubule polymerization in addition to inhibiting c-MET.

SUBMITTER: Katayama R 

PROVIDER: S-EPMC3759033 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Katayama Ryohei R   Aoyama Aki A   Yamori Takao T   Qi Jie J   Oh-hara Tomoko T   Song Youngchul Y   Engelman Jeffrey A JA   Fujita Naoya N  

Cancer research 20130418 10


The receptor tyrosine kinase c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF). The HGF/c-MET axis is often dysregulated in tumors. c-MET activation can be caused by MET gene amplification, activating mutations, and auto- or paracrine mechanisms. Thus, c-MET inhibitors are under development as anticancer drugs. Tivantinib (ARQ 197) was reported as a small-molecule c-MET inhibitor and early clinical studies suggest antitumor activity. To assess whether the antitumor activ  ...[more]

Similar Datasets

| S-EPMC5528687 | biostudies-literature
| S-EPMC4372650 | biostudies-literature
| S-EPMC5406425 | biostudies-literature
| S-EPMC4673154 | biostudies-literature
| 2147788 | ecrin-mdr-crc
| S-EPMC3553536 | biostudies-literature
| S-EPMC5736844 | biostudies-literature
| S-EPMC3121448 | biostudies-literature
| S-EPMC6010293 | biostudies-literature
| S-EPMC3228218 | biostudies-literature